ONCSQ: AI 评分 52/100 — AI 分析 (4月 2026)

OncoSec Medical Incorporated is a late-stage immuno-oncology company focused on developing DNA-based therapeutics for cancer treatment. The company filed for liquidation under Chapter 7 bankruptcy in June 2023.

Key Facts: AI Score: 52/100 Sector: Healthcare

公司概况

概要：

OncoSec Medical Incorporated, an immuno-oncology company, focused on intra-tumoral DNA-based therapeutics to stimulate anti-tumor immune responses. Despite clinical trial collaborations with Merck and Duke University, the company filed for Chapter 7 liquidation in 2023, impacting its pipeline of cancer treatments and COVID-19 therapies. The company's stock trades on the OTC market.

ONCSQ是做什么的？

OncoSec Medical Incorporated, formerly known as NetVentory Solutions Inc., was founded in 2008 and rebranded in March 2011 to focus on immuno-oncology. Headquartered in Pennington, New Jersey, the company specialized in designing, developing, and commercializing intra-tumoral DNA-based therapeutics aimed at stimulating and augmenting anti-tumor immune responses for cancer treatment. Their product pipeline included KEYNOTE-695, a Phase 2 trial for advanced melanoma, and TAVO + SARS-CoV-2 spike glycoprotein, a Phase 1 clinical trial for COVID-19. Additional trials included TAVO + epacadostat + pembrolizumab for squamous cell carcinoma of the head and neck, TAVO + nivolumab for breast cancer, and TAVO + CXCL9 for solid tumors, along with OMS-100 and OMS-102 for metastatic melanoma. OncoSec collaborated with Merck & Co., Inc. on KEYNOTE-695 and KEYNOTE-890 and with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination with a HER2-plasmid vaccine. However, on June 14, 2023, OncoSec filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey, ceasing its operations and development programs.

ONCSQ的投资论点是什么？

OncoSec Medical Incorporated's Chapter 7 liquidation filing in June 2023 represents a significant event for investors. The company's pipeline, which included multiple Phase 1 and Phase 2 clinical trials, is now subject to the bankruptcy proceedings. Key collaborations with Merck and Duke University are unlikely to continue. The company's market capitalization was $0.00B prior to liquidation. The high beta of 9.96 indicates extreme volatility, which is now largely irrelevant given the bankruptcy. Investors should be aware that recovery on OTC stocks after bankruptcy is highly uncertain.

ONCSQ在哪个行业运营？

OncoSec Medical Incorporated operated within the competitive biotechnology industry, focusing on immuno-oncology. This sector involves developing therapies that harness the body's immune system to fight cancer. The industry is characterized by high research and development costs, lengthy clinical trial processes, and regulatory hurdles. Companies like OncoSec often collaborate with larger pharmaceutical firms to fund and conduct clinical trials. The failure rate for biotechnology companies is high, and OncoSec's bankruptcy reflects the challenges inherent in bringing novel therapies to market. Competitors focus on similar immuno-oncology approaches, creating a crowded and dynamic landscape.

Biotechnology

Healthcare

ONCSQ有哪些增长机遇？

N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.

OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023.
The company's market capitalization was $0.00B prior to liquidation.
The company's pipeline included multiple Phase 1 and Phase 2 clinical trials targeting various cancers and COVID-19.
OncoSec had clinical trial collaborations with Merck & Co., Inc. and research collaboration with Duke University.
The stock trades on the OTC market, specifically the OTC Other tier.

ONCSQ提供哪些产品和服务？

Developed intra-tumoral DNA-based therapeutics.
Focused on stimulating anti-tumor immune responses.
Conducted Phase 1 and Phase 2 clinical trials for cancer treatments.
Developed a COVID-19 therapy in Phase 1 clinical trial.
Collaborated with Merck & Co., Inc. on clinical trials.
Partnered with Duke University for research.

ONCSQ如何赚钱？

Focused on developing and commercializing immuno-oncology therapeutics.
Generated revenue through potential future sales of approved therapies.
Relied on collaborations and partnerships for funding and clinical trials.

Patients with advanced melanoma.
Patients with squamous cell carcinoma of the head and neck.
Patients with breast cancer.
Patients with solid tumors.
Patients with COVID-19.

Proprietary intra-tumoral DNA-based therapeutic technology.
Clinical trial collaborations with Merck & Co., Inc. and Duke University.
Pipeline of Phase 1 and Phase 2 clinical trials.

什么因素可能推动ONCSQ股价上涨？

N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023.

ONCSQ的主要风险是什么？

Ongoing: Chapter 7 bankruptcy proceedings.
Ongoing: Loss of intellectual property.
Ongoing: Inability to continue clinical trials.
Potential: Legal claims from creditors.
Potential: Delisting from the OTC market.

ONCSQ的核心优势是什么？

Proprietary DNA-based therapeutic technology.
Clinical trial collaborations with established institutions.
Diverse pipeline of immuno-oncology treatments.

ONCSQ的劣势是什么？

Chapter 7 liquidation filing.
Dependence on collaborations for funding.
High risk of clinical trial failure.

ONCSQ有哪些机遇？

N/A due to liquidation filing.

ONCSQ面临哪些威胁？

Bankruptcy proceedings.
Loss of intellectual property.
Inability to continue clinical trials.

ONCSQ的竞争对手是谁？

Atrion Medical, Inc. — Focuses on medical devices rather than immuno-oncology. — (ATRX)
Cadex Exploration Inc — Operates in the oil and gas sector, unrelated to biotechnology. — (CDXI)
Longboard, Inc. — Focuses on restaurant and hospitality, unrelated to biotechnology. — (LGBI)
ModCon Living, Inc. — Focuses on modular construction, unrelated to biotechnology. — (MODC)
Motion Solutions, Inc. — Focuses on industrial automation, unrelated to biotechnology. — (MOTS)

Key Metrics

MoonshotScore: 52/100

Company Profile

Headquarters: Pennington, US
Employees: 40
Founded: 2010

AI Insight

AI analysis pending for ONCSQ

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does OncoSec Medical Incorporated do?

OncoSec Medical Incorporated was a late-stage immuno-oncology company focused on developing intra-tumoral DNA-based therapeutics to stimulate anti-tumor immune responses for cancer treatment. The company's pipeline included treatments for melanoma, squamous cell carcinoma, breast cancer, solid tumors, and COVID-19. OncoSec collaborated with Merck & Co., Inc. and Duke University to advance its clinical trials. However, the company filed for Chapter 7 liquidation in June 2023, ceasing its operations and development programs.

What do analysts say about ONCSQ stock?

Given OncoSec Medical Incorporated's Chapter 7 liquidation filing in June 2023, there is no current analyst coverage or consensus. The company's stock trades on the OTC market, and its financial viability is highly uncertain. Investors should be aware that the company is undergoing bankruptcy proceedings, and any prior valuations or growth considerations are no longer applicable. Trading in this stock carries substantial risk.

What are the main risks for ONCSQ?

The primary risk for ONCSQ is the Chapter 7 bankruptcy filing, which indicates that the company is undergoing liquidation. This means that the company's assets will be sold to pay off creditors, and there is a high likelihood that shareholders will receive little to no recovery. Additional risks include the loss of intellectual property, the inability to continue clinical trials, and potential legal claims from creditors. The stock's OTC listing further increases the risk due to limited regulatory oversight and low liquidity.